CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Royalty income	$ 2,189	$ 174
Collaboration revenue	242	65
Other revenues	19	9
Total revenue	2,450	248
Operating expenses:
Research and development	9,149	6,489
General and administrative	5,817	3,725
Change in contingent consideration liability	200	300
Total operating expenses	15,166	10,514
Operating loss	(12,716)	(10,266)
Other income:
Interest income	43	12
Total other income	43	12
Net loss	(12,673)	(10,254)
Net loss attributable to noncontrolling interests	(18)	0
Net loss attributable to Progenics	$ (12,655)	$ (10,254)
Net loss per share attributable to Progenics - basic and diluted	$ (0.18)	$ (0.15)
Weighted-average shares - basic and diluted	69,946	69,637